Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9643-9653

  Cavallaro, Cullen L ^a   Briceno, Stephanie ^a   Chen, Jing ^a   Cvijic, Mary Ellen ^a   Davies, Paul ^a   Hynes, John ^a   Liu, Rui Qin ^a   Mandlekar, Sandhya ^a   Rose, Anne V ^a   Tebben, Andrew J ^a   Van Kirk, Katy ^a   Watson, Andrew ^a   Wu, Hong ^a   Yang, Guchen ^a   Carter, Percy H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1;

AMINO TERMINAL SEQUENCE; ARTICLE; DRUG SYNTHESIS; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM; CELLS, CULTURED; CHEMOTAXIS; HUMANS; MICE; MICROSOMES, LIVER; MONOCYTES; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PROTEIN BINDING; RABBITS; RATS; RECEPTORS, CCR; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 84870039558     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300896d     Document Type: Article

References (32)

1. Allen, S. J.; Crown, S. E.; Handel, T. M. Chemokine:receptor structure, interactions, and antagonism Annu. Rev. Immunol. 2007, 25, 787-820
2. Viola, A.; Luster, A. D. Chemokines and their receptors: drug targets in immunity and inflammation Annu. Rev. Pharmacol. Toxicol. 2008, 48, 171-197
3. Horuk, R. Chemokine receptor antagonists: overcoming developmental hurdles Nat. Rev. Drug Discovery 2009, 8, 23-33
4. Schall, T. J.; Proudfoot, A. E. Overcoming hurdles in developing successful drugs targeting chemokine receptors Nat. Rev. Immunol. 2011, 11, 355-363
5. Horuk, R. Targeting CCR1. Methods Princ. Med. Chem. 2011, 46 (Chemokine Receptors as Drug Targets), 323-338.
6. Review: Cheng, J.-F.; Jack, R. CCR1 antagonists Mol. Diversity 2008, 12, 17-23
7. Carter, P. H.; Hynes, J. N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338 Expert Opin. Ther. Pat. 2010, 20, 1609-1618
8. Merritt, J. R.; James, R.; Paradkar, V. M.; Zhang, C.; Liu, R.; Liu, J.; Jacob, B.; Chiriac, C.; Ohlmeyer, M. J.; Quadros, E.; Wines, P.; Postelnek, J.; Hicks, C. M.; Chen, W.; Kimble, E. F.; O'Brien, L.; White, N.; Desai, H.; Appell, K. C.; Webb, M. L. Novel pyrrolidine heterocycles as CCR1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 5477-5479
9. Gladue, R. P.; Brown, M. F.; Zwillich, S. H. CCR1 antagonists: what have we learned from clinical trials Curr. Top. Med. Chem. 2010, 10, 1268-1277
10. Liang, M.; Mallari, C.; Rosser, M.; Ng, H. P.; May, K.; Monahan, S.; Bauman, J. G.; Islam, I.; Ghannam, A.; Buckman, B.; Shaw, K.; Wei, G. P.; Xu, W.; Zhao, Z.; Ho, E.; Shen, J.; Oanh, H.; Subramanyam, B.; Vergona, R.; Taub, D.; Dunning, L.; Harvey, S.; Snider, R. M.; Hesselgesser, J.; Morrissey, M. M.; Perez, H. D. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1 J. Biol. Chem. 2000, 275, 19000-19008
11. Gladue, R. P.; Tylaska, L. A.; Brissette, W. H.; Lira, P. D.; Kath, J. C.; Poss, C. S.; Brown, M. F.; Paradis, T. J.; Conklyn, M. J.; Ogborne, K. T.; McGlynn, M. A.; Lillie, B. M.; DiRico, A. P.; Mairs, E. N.; McElroy, E. B.; Martin, W. H.; Stock, I. A.; Shepard, R. M.; Showell, H. J.; Neote, K. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases J. Biol. Chem. 2003, 278, 40473-40480
12. Structure suggested from a patent analysis, as described in: Norman, P. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653 Expert Opin. Ther. Pat. 2009, 19, 1629-1633
13. Lu, C.; Balani, S. K.; Qian, M. G.; Prakash, S. R.; Ducray, P. S.; von Moltke, L. L. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist J. Pharm. Exp. Ther. 2010, 332, 562-568
14. Haringman, J. J.; Kraan, M. C.; Smeets, T. J. M.; Zwinderman, A. H.; Tak, P. P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis Ann. Rheum. Dis. 2003, 62, 715-721
15. Borregaard, J.; Skov, L.; Wang, L.; Ting, N.; Wang, C.; Beck, L. A.; Sonne, J.; Clucas, A. Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects Contact Dermatitis 2008, 59, 212-219
16. Vergunst, C. E.; Gerlag, D. M.; von Moltke, L.; Karol, M.; Wyant, T.; Chi, X.; Matzkin, E.; Leach, T.; Tak, P. P. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study Arthritis Rheum. 2009, 60, 3572-3581
17. Zipp, F.; Hartung, H.-P.; Hillert, J.; Schimrigk, S.; Trebst, C.; Stangel, M.; Infante-Duarte, C.; Jakobs, P.; Wolf, C.; Sandbrink, R.; Pohl, C.; Filippi, M. CCR1 Antagonist Study Group. Blockade of chemokine signaling in patients with multiple sclerosis Neurology 2006, 67, 1880-1883
18. Kerstjens, H. A.; Bjermer, L.; Eriksson, L.; Dahlstrom, K.; Vestbo, J. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients Respir. Med. 2010, 104, 1297-1303
19. Lebre, M. C.; Vergunst, C. E.; Choi, I. Y. K.; Aarrass, S.; Oliveira, A. S. F.; Wyant, T.; Horuk, R.; Reedquist, K. A.; Tak, P. P. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis PLoS One 2011, 6, e21772
20. The structure has not been formally disclosed, but several patent applications from Chemocentryx claim a single compound. For example, see: Li, L.; Pennell, A. M. K.; Zhang, P. 3-(Imidazolyl)-pyrazolo[3,4b]-pyridines. US Patent application US 2010/0173911 A1.
21. Dairaghi, D. J.; Zhang, P.; Wang, Y.; Seitz, L. C.; Johnson, D. A.; Miao, S.; Ertl, L. S.; Zeng, Y.; Powers, J. P.; Pennell, A. M.; Bekker, P.; Schall, T. J.; Jaen, J. C. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: Implications for selection of clinical dose Clinical Pharm. Ther. 2011, 89, 726-734
22. CCX354 is listed as in an active clinical trial on www.clinicaltrials.gov (accessed Aug 10, 2011). See trial identifier NCT01242917, "A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy (CARAT-2)".
23. Tak, P. P.; Balanescu, A.; Tseluyko, V.; Bojin, S.; Drescher, E.; Dairaghi, D.; Miao, S.; Marchesin, V.; Jaen, J.; Bekker, P.; Schall, T. J. Safety and efficacy of oral chemokine receptor 1 antagonist CCX354-C in a phase 2 rheumatoid arthritis study. Presented at the ACR/ARHP Scientific Meeting, Chicago, IL, November 5-9, 2011; Presentation L11.
24. Xie, Y. F.; Sircar, I.; Lake, K.; Komandla, M.; Ligsay, K.; Li, J.; Xu, K.; Parise, J.; Schneider, L.; Huang, D.; Liu, J.; Sakurai, N.; Barbosa, M.; Jack, R. Identification of novel series of human CCR1 antagonists Bioorg. Med. Chem. Lett. 2008, 18, 2215-2221
25. Merritt, J. R.; Liu, J.; Quadros, E.; Morris, M. L.; Liu, R.; Zhang, R.; Jacob, B.; Postelnek, J.; Hicks, C. M.; Chen, W.; Kimble, E. F.; Rogers, W. L.; O'Brien, L.; White, N.; Desai, H.; Bansal, S.; King, G.; Ohlmeyer, M. J.; Appell, K. C.; Webb, M. L. Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists J. Med. Chem. 2009, 52, 1295-1301
26. Naya, A.; Sagara, Y.; Ohwaki, K.; Saeki, T.; Ichikawa, D.; Iwasawa, Y.; Noguchi, K.; Ohtake, N. Design, synthesis, and discovery of a novel CCR1 antagonist J. Med. Chem. 2001, 44, 1429-1435
27. Xie, Y. F.; Lake, K.; Ligsay, K.; Komandla, M.; Sircar, I.; Nagarajan, G.; Li, J.; Xu, K.; Parise, J.; Schneider, L.; Huang, D.; Liu, J.; Dines, K.; Sakurai, N.; Barbosa, M.; Jack, R. Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists Bioorg. Med. Chem. Lett. 2007, 17, 3367-3372
28. Revesz, L.; Bollbuck, B.; Buhl, T.; Eder, J.; Esser, R.; Feifel, R.; Heng, R.; Hiestand, P.; Jachez-Demange, B.; Loetscher, P.; Sparrer, H.; Schlapbach, A.; Waelchli, R. Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis Bioorg. Med. Chem. Lett. 2005, 15, 5160-5164
29. Liang, M.; Rosser, M.; Ng, H. P.; May, K.; Bauman, J. G.; Islam, I.; Ghannam, A.; Kretschmer, P. J.; Pu, H.; Dunning, L.; Snider, R. M.; Morrissey, M. M.; Hesselgesser, J.; Perez, H. D.; Horuk, R. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor Eur. J. Pharmacol. 2000, 389, 41-49
30. Onuffer, J.; McCarrick, M. A.; Dunning, L.; Liang, M.; Rosser, M.; Wei, G.-P.; Ng, H.; Horuk, R. Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1 J. Immunol. 2003, 170, 1910-1916
31. Vaidehi, N.; Schlyer, S.; Trabanino, R. J.; Floriano, W. B.; Abrol, R.; Sharma, S.; Kochanny, M.; Koovakat, S.; Dunning, L.; Liang, M.; Fox, J. M.; Lopes de Mendonca, F.; Pease, J. E.; Goddard, W. A., III; Horuk, R. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation J. Biol. Chem. 2006, 281, 27613-27620
32. Wu, S. C.; Yoon, D.; Chin, J.; van Kirk, K.; Seethala, R.; Golla, R.; He, B.; Harrity, T.; Kunselman, L. K.; Morgan, N. N.; Ponticiello, R. P.; Taylor, J. R.; Zebo, R.; Harper, T. W.; Li, W.; Wang, M.; Zhang, L.; Sleczka, B. G.; Nayeem, A.; Sheriff, S.; Camac, D. M.; Morin, P. E.; Everlof, J. G.; Li, Y.-X.; Ferraro, C. A.; Kieltyka, K.; Shou, W.; Vath, M. B.; Zvyaga, T. A.; Gordon, D. A.; Robl, J. A. Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1) Bioorg. Med. Chem. Lett. 2011, 21, 6693-6698